IDIOPATHIC PULMONARY FIBROSIS
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Race against time: can new drugs slow scarring of the lungs?
Disease control TerminatedThis study aimed to test whether new investigational drugs could slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Adults with IPF were randomly assigned to receive either an experimental treatment or a placebo for 26 weeks to see if it…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Drug trial aims to put the brakes on scarred lungs
Disease control TerminatedThis study tested whether an investigational drug called vixarelimab could slow the decline in lung function for people with two types of progressive lung scarring diseases. About 286 adults with either idiopathic pulmonary fibrosis or lung disease related to systemic sclerosis (…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Sleep machine tested to fight scarred lungs
Disease control TerminatedThis study looked at whether using a CPAP machine for sleep apnea could also help reduce abnormal acid reflux and lung inflammation in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Participants with both IPF and sleep apnea were randomly assign…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: NA • Sponsor: University of Arizona • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Race for new lung scarring treatment hits clinical trial hurdle
Disease control TerminatedThis study tested an experimental oral drug called HZN-825 to see if it could slow the progression of lung scarring in people with idiopathic pulmonary fibrosis (IPF). About 153 participants were randomly assigned to receive either the drug at one of two doses or a placebo for on…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Race for new IPF treatment: can experimental drug slow deadly lung scarring?
Disease control TerminatedThis study tested a new drug, GSK3915393, to see if it could slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring and makes breathing difficult. About 158 people with IPF were randomly assigned to receive either the ne…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Drug trial aims to quiet debilitating cough in scarred lungs
Symptom relief TerminatedThis study tested an oral medicine called BI 1839100 to see if it could reduce chronic cough in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). About 85 participants were randomly assigned to receive either the study drug at different dose…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated Mar 27, 2026 12:41 UTC